Chong Kun Dang Pharmaceutical Corp – Product Pipeline Review

Global Markets Direct’s, ‘Chong Kun Dang Pharmaceutical Corp – Product Pipeline Review – 2016’, provides an overview of the Chong Kun Dang Pharmaceutical Corp’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp

The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Chong Kun Dang Pharmaceutical Corp’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Chong Kun Dang Pharmaceutical Corp’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Chong Kun Dang Pharmaceutical Corp’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Chong Kun Dang Pharmaceutical Corp Snapshot 6

Chong Kun Dang Pharmaceutical Corp Overview 6

Key Facts 6

Chong Kun Dang Pharmaceutical Corp - Research and Development Overview 7

Key Therapeutic Areas 7

Chong Kun Dang Pharmaceutical Corp - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance 13

Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Chong Kun Dang Pharmaceutical Corp - Drug Profiles 17

(amlodipine besylate + candesartan cilexetil) - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

(atorvastatin calcium + choline fenofibrate) - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

(atorvastatin calcium + ezetimibe) - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

(lobeglitazone + metformin hydrochloride XR) - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

(tadalafil + tamsulosin hydrochloride) - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

CKD-390 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

CKD-504 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CKD-506 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CKD-516 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CKD-519 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CKD-581 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CKD-L - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

darbepoetin alfa - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

difelikefalin - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

hyaluronate sodium - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

leuprolide acetate SR - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

levocabastine hydrochloride + mometasone furoate - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LT-1001 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

nepodin - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

pegfilgrastim - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

pregabalin SR - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ranibizumab biosimilar - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

tamsulosin hydrochloride SR - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis 52

Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target 52

Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration 54

Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type 55

Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action 56

Chong Kun Dang Pharmaceutical Corp - Dormant Projects 58

Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products 59

Discontinued Pipeline Product Profiles 59

beloranib 59

Chong Kun Dang Pharmaceutical Corp - Company Statement 60

Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Chong Kun Dang Pharmaceutical Corp, Key Facts 6

Chong Kun Dang Pharmaceutical Corp – Pipeline by Indication, 2016 8

Chong Kun Dang Pharmaceutical Corp – Pipeline by Stage of Development, 2016 10

Chong Kun Dang Pharmaceutical Corp – Monotherapy Products in Pipeline, 2016 11

Chong Kun Dang Pharmaceutical Corp – Combination Treatment Modalities in Pipeline, 2016 12

Chong Kun Dang Pharmaceutical Corp – Phase III, 2016 13

Chong Kun Dang Pharmaceutical Corp – Phase II, 2016 14

Chong Kun Dang Pharmaceutical Corp – Phase I, 2016 15

Chong Kun Dang Pharmaceutical Corp – Preclinical, 2016 16

Chong Kun Dang Pharmaceutical Corp – Pipeline by Target, 2016 53

Chong Kun Dang Pharmaceutical Corp – Pipeline by Route of Administration, 2016 54

Chong Kun Dang Pharmaceutical Corp – Pipeline by Molecule Type, 2016 55

Chong Kun Dang Pharmaceutical Corp – Pipeline Products by Mechanism of Action, 2016 57

Chong Kun Dang Pharmaceutical Corp – Dormant Developmental Projects,2016 58

Chong Kun Dang Pharmaceutical Corp – Discontinued Pipeline Products, 2016 59

Chong Kun Dang Pharmaceutical Corp, Other Locations 61

List of Figures

List of Figures

Chong Kun Dang Pharmaceutical Corp – Pipeline by Top 10 Indication, 2016 8

Chong Kun Dang Pharmaceutical Corp – Pipeline by Stage of Development, 2016 10

Chong Kun Dang Pharmaceutical Corp – Monotherapy Products in Pipeline, 2016 11

Chong Kun Dang Pharmaceutical Corp – Pipeline by Top 10 Target, 2016 52

Chong Kun Dang Pharmaceutical Corp – Pipeline by Route of Administration, 2016 54

Chong Kun Dang Pharmaceutical Corp – Pipeline by Molecule Type, 2016 55

Chong Kun Dang Pharmaceutical Corp – Pipeline Products by Top 10 Mechanism of Action, 2016 56

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports